Dawid Walerych - Search Results

Year	Number of Results
2004	2
2005	1
2010	2
2011	1
2012	1
2014	1
2015	1
2016	4
2017	3
2018	2
2020	1
2021	1
2022	1
2024	0

1

Multi-omics reveals global effects of mutant p53 gain-of-function.

Walerych D, Lisek K, Del Sal G. Walerych D, et al. Cell Cycle. 2016 Nov 16;15(22):3009-3010. doi: 10.1080/15384101.2016.1215703. Epub 2016 Jul 26. Cell Cycle. 2016. PMID: 27458655 Free PMC article. No abstract available.

2

The molecular network of the proteasome machinery inhibition response is orchestrated by HSP70, revealing vulnerabilities in cancer cells.

Oroń M, Grochowski M, Jaiswar A, Legierska J, Jastrzębski K, Nowak-Niezgoda M, Kołos M, Kaźmierczak W, Olesiński T, Lenarcik M, Cybulska M, Mikula M, Żylicz A, Miączyńska M, Zettl K, Wiśniewski JR, Walerych D. Oroń M, et al. Among authors: walerych d. Cell Rep. 2022 Sep 27;40(13):111428. doi: 10.1016/j.celrep.2022.111428. Cell Rep. 2022. PMID: 36170818 Free article.

3

Targeting mutant p53 in cancer: a long road to precision therapy.

Mantovani F, Walerych D, Sal GD. Mantovani F, et al. Among authors: walerych d. FEBS J. 2017 Mar;284(6):837-850. doi: 10.1111/febs.13948. Epub 2016 Nov 20. FEBS J. 2017. PMID: 27808469 Free article. Review.

4

Mutant p53: One, No One, and One Hundred Thousand.

Walerych D, Lisek K, Del Sal G. Walerych D, et al. Front Oncol. 2015 Dec 21;5:289. doi: 10.3389/fonc.2015.00289. eCollection 2015. Front Oncol. 2015. PMID: 26734571 Free PMC article. Review.

5

Cooperation of p53 mutations with other oncogenic alterations in cancer.

Girardini JE, Walerych D, Del Sal G. Girardini JE, et al. Among authors: walerych d. Subcell Biochem. 2014;85:41-70. doi: 10.1007/978-94-017-9211-0_3. Subcell Biochem. 2014. PMID: 25201188 Review.

6

The rebel angel: mutant p53 as the driving oncogene in breast cancer.

Walerych D, Napoli M, Collavin L, Del Sal G. Walerych D, et al. Carcinogenesis. 2012 Nov;33(11):2007-17. doi: 10.1093/carcin/bgs232. Epub 2012 Jul 20. Carcinogenesis. 2012. PMID: 22822097 Free PMC article. Review.

7

A Driver Never Works Alone-Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer.

Grzes M, Oron M, Staszczak Z, Jaiswar A, Nowak-Niezgoda M, Walerych D. Grzes M, et al. Among authors: walerych d. Cancers (Basel). 2020 Jun 11;12(6):1532. doi: 10.3390/cancers12061532. Cancers (Basel). 2020. PMID: 32545208 Free PMC article. Review.

8

Mutant p53-Nrf2 axis regulates the proteasome machinery in cancer.

Lisek K, Walerych D, Del Sal G. Lisek K, et al. Among authors: walerych d. Mol Cell Oncol. 2016 Sep 2;4(1):e1217967. doi: 10.1080/23723556.2016.1217967. eCollection 2017. Mol Cell Oncol. 2016. PMID: 28197530 Free PMC article.

9

Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1.

Tosi A, Dalla Santa S, Cappuzzello E, Marotta C, Walerych D, Del Sal G, Zanovello P, Sommaggio R, Rosato A. Tosi A, et al. Among authors: walerych d. Oncoimmunology. 2017 Apr 5;6(8):e1313371. doi: 10.1080/2162402X.2017.1313371. eCollection 2017. Oncoimmunology. 2017. PMID: 28919988 Free PMC article.

10

Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells.

Lisek K, Campaner E, Ciani Y, Walerych D, Del Sal G. Lisek K, et al. Among authors: walerych d. Oncotarget. 2018 Apr 17;9(29):20508-20523. doi: 10.18632/oncotarget.24974. eCollection 2018 Apr 17. Oncotarget. 2018. PMID: 29755668 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

19 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year